Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Liabilities (2019 - 2025)

BridgeBio Pharma's Total Liabilities history spans 7 years, with the latest figure at $3.0 billion for Q4 2025.

  • For Q4 2025, Total Liabilities rose 26.72% year-over-year to $3.0 billion; the TTM value through Dec 2025 reached $3.0 billion, up 26.72%, while the annual FY2025 figure was $3.0 billion, 26.72% up from the prior year.
  • Total Liabilities for Q4 2025 was $3.0 billion at BridgeBio Pharma, up from $2.9 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $3.0 billion in Q4 2025 and bottomed at $1.5 billion in Q1 2021.
  • The 5-year median for Total Liabilities is $1.9 billion (2022), against an average of $2.0 billion.
  • The largest annual shift saw Total Liabilities surged 215.32% in 2021 before it decreased 1.28% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $1.9 billion in 2021, then dropped by 0.55% to $1.9 billion in 2022, then grew by 1.12% to $1.9 billion in 2023, then rose by 25.84% to $2.4 billion in 2024, then rose by 26.72% to $3.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Total Liabilities are $3.0 billion (Q4 2025), $2.9 billion (Q3 2025), and $2.9 billion (Q2 2025).